Who we are
Eckert & Ziegler Radiopharma represents the combined efforts of two of the Eckert & Ziegler group’s business units. Its headquarter is located in Berlin, Germany.
With more than a decade of experience, we are one of the leading experts in nuclear medicine and molecular imaging offering individual, valuable and innovative solutions and services for the diagnosis and treatment of different diseases.
A team of highly qualified employees and a strong network of international partners give us the ability to detect and set trends in the market, reinvent ourselves as well as our products and thus prepare you for future challenges.
Long-term experience meets customer-focused innovation
More than a decade of experience and high-qualified personnel are the keys to face our customers’ challenges.
Highest quality meets broad portfolio
Advancement and continuous improvement provide the basis for our work attitude.
International network meets local trends
Global partners complete our pursuit to offer tailored solutions.
We contribute to personalized medicine as an expert and your strong partner in the field of nuclear medicine and radiochemistry. Our core competence is the provision of pharmaceutical services as well as versatile, innovative and high-quality technical solutions. Our expertise in trivalent metals for theranostic purposes empowers us to support ambitious startups and institutions with knowhow, technical and radiochemical support as well as financial assistance. Our well established network of production sites produces different radiopharmaceutical products for compound labeling. Furthermore, we offer contract manufacturing of medicinal products or components for clinical trial supply as well as commercial purposes.
Although Eckert & Ziegler Radiopharma consists of different companies, we act in concert. Whether customers require a full package of radiopharmaceuticals, synthesis equipment and quality control or internal exchange of knowledge becomes necessary, our almost 120 colleagues cooperate to offer individual, valuable and innovative solutions. The highly qualified team comprises expertise in product design, electromechanics, radiochemistry, radiopharmaceutical production, software programming, quality assurance, logistics, business development, regulatory, service, sales, marketing and more. These professional skills combined with short communication paths make us cope with most complex challenges as a team.
Although the Radiopharma Business segment consists of eight different companies, we act in concert. Whether customers require a full package of radiopharmaceuticals, synthesis equipment and quality control or internal exchange of knowledge becomes necessary, our more than 140 colleagues cooperate to offer individual, valuable and innovative solutions.
The highly qualified team comprises expertise in product design, electromechanics, radiochemistry, radiopharmaceutical production, software programming, quality assurance, logistics, business development, regulatory, service, sales, marketing and more. These professional skills combined with short communication paths make us cope with most complex challenges as a team.
Eckert & Ziegler Radiopharma is corporate member of a number of organizations and associations promoting the advancement of nuclear medicine in Germany, Europe and the World. This inludes Nuclear Medicine Europe (NMEu), the European Association of Nuclear Medicine (EANM), the World Association of Radiopharmaceutical Molecular Therapy (WARMTH), the German Society for Nuclear Medicine e.V. (DGN) and the professional association of German nuclear medicine practitioners – Berufsverband Deutscher Nuklearmediziner e.V. (BDN).
1992 Founding of BEBIG Isotopentechnik und Umweltdiagnostik GmbH (BEBIG GmbH), Berlin by Dr. Andreas Eckert and Jürgen Ziegler – The beginning of Eckert & Ziegler
1995 Development of Radiopharma Segment by founding EUROTOPE Entwicklungsgesellschaft für Isotopentechnologien mbH, Berlin – a company that developed production lines, special sources and recycling processes for radioactive materials.
1997 Founding of Eckert & Ziegler Strahlen- und Medizintechnik AG, Berlin as the holding company for a number of specialized subsidiaries.
2000 Registration of FDG-EZAG (Fludeoxyglucose (18F)).
2005 Acquisition of 51% of the shares of f-con Europe GmbH.
2005 Acquisition of 70% of EURO-PET Berlin Zyklotron GmbH, Berlin.
2006 Registration of Yttriga ([90Y]Yttrium chloride, radiopharmaceutical precursor, sterile solution) in several European countries.
2006 The beginning of our synthesis devices: Modular-Lab Standard – a new approach of automated radiosynthesis.
2009 Acquisition of the isotope specialist Nuclitec GmbH, Braunschweig.
2009 Modular-Lab PharmTracer – A cassette-based solution for routine production.
2011 Acquisition of the Analytic Instrumentation and Radiochemistry Equipment Business from American market leader Bioscan, Inc. – the perfect complement to the existing Eckert & Ziegler Analytical Equipment.
2013 Modular-Lab eazy – the smallest automated synthesis system on the market.
2014 Approval of GalliaPharm® – the world’s first, approved 68Ge/68Ga radionuclide generator for positron emission tomography (PET) in the diagnosis of cancer.
2015 Registration of GalliaPharm® as a drug product in 12 countries of the European Union finalized.
2015 FDA Inspection of GalliaPharm® manufacturing facility in Berlin successfully passed.
2016 AAA’s NETSPOT® Gallium Ga 68 dotatate kit approval in the USA links GalliaPharm® as the source of the 68Ga.
2016 European Commission has approved SomaKit TOC™ (AAA), a kit for radiopharmaceutical preparation of gallium (68Ga) edotreotide solution for injection for PET with GalliaPharm® as the source of the 68Ga.
2017 Eckert & Ziegler Radiopharma sells its cyclotron division to Alliance Medical.
2018 KitLab – Fully automated and user-friendly stand-alone device for safe processing of cold kits.
2019 Additional production capacities for GalliaPharm® released by supervisory authorities.
2020 Start of Commercial Production of Lutetium-177.
2020 Eckert & Ziegler joins Nuclear Medicine Europe – the industry association.